Zollinger‑Ellison Clinical Syndrome: A Patient‑Focused Guide
Overview
Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors, called gastrinomas, develop in the pancreas or duodenum. These neuroendocrine tumors secrete excessive amounts of the hormone gastrin, which overstimulates the stomach’s acid‑producing cells. The resulting hyperacidity leads to severe peptic ulcers, diarrhea, and malabsorption.
Who it affects: ZES can occur at any age, but most patients are diagnosed between 30 and 60 years old. Both men and women are affected, with a slight male predominance in some series (≈55 % male). Approximately 20–25 % of cases are linked to the inherited disorder multiple endocrine neoplasia type 1 (MEN‑1), while the remaining cases are sporadic.[1] Mayo Clinic
Prevalence: The overall incidence is estimated at 0.5–2 cases per million people per year, making ZES one of the rarest endocrine tumor syndromes.[2] NIH
Symptoms
The hallmark of ZES is gastric acid hypersecretion, which can manifest in a wide range of gastrointestinal (GI) and systemic symptoms. The severity often correlates with tumor size and gastrin level.
Gastrointestinal Symptoms
- Refractory peptic ulcers – ulcers that persist despite standard proton‑pump inhibitor (PPI) therapy; usually multiple and may be located beyond the duodenum (e.g., jejunum).
- Abdominal pain – crampy or burning pain, often post‑prandial.
- Diarrhea – watery, sometimes fatty (steatorrhea) due to bile‑acid malabsorption caused by low‑pH inactivation of pancreatic enzymes.
- Nausea & vomiting – can be triggered by ulcer pain or gastric outlet obstruction.
- Gastroesophageal reflux disease (GERD) – heartburn from excessive acid.
- Weight loss – secondary to malabsorption and chronic diarrhea.
Systemic / Extra‑intestinal Symptoms
- Fatigue – often related to anemia from chronic blood loss.
- Iron‑deficiency anemia – occult GI bleeding.
- Osteopenia / osteoporosis – chronic acid load may affect calcium metabolism.
- Skin changes – occasional flushing or itching, especially in MEN‑1 patients.
Causes and Risk Factors
Underlying Pathophysiology
ZES is caused by gastrin‑producing neuroendocrine tumors (NETs). Gastrin stimulates the parietal cells of the stomach to secrete hydrochloric acid. In ZES, gastrin levels are typically >10‑fold the upper limit of normal, driving acid output >5‑10 L per day (versus <0.5 L in healthy adults). This extreme acidity overwhelms the mucosal protective mechanisms, producing ulcer disease.
Risk Factors
- MEN‑1 syndrome – a hereditary mutation (MEN1 gene) that predisposes to pancreatic NETs, parathyroid, and pituitary tumors. Up to 25 % of ZES patients have MEN‑1.[3] Cleveland Clinic
- Family history of gastrinomas – rare but increases risk.
- Chronic atrophic gastritis – may elevate gastrin, but does not cause true ZES.
- Smoking – associated with NET development in several studies.
- Age > 30 years – sporadic cases tend to appear later in life.
Diagnosis
Because symptoms overlap with common peptic ulcer disease, a high index of suspicion is essential, especially when ulcers are refractory, multiple, or located distal to the duodenum.
Laboratory Tests
- Fasting serum gastrin – a level >100 pg/mL (or >10 × upper limit) strongly suggests ZES, but must be interpreted in the context of gastric pH.
- Secretin stimulation test – administration of secretin (normally suppresses gastrin) paradoxically raises gastrin >120 pg/mL in gastrinomas; >30 % increase is diagnostic.[4] WHO
- Gastric pH – a pH < 2 confirms acid hypersecretion.
- Chromogranin A – a general NET marker; useful for monitoring.
Imaging Studies
- Endoscopic ultrasound (EUS) – high‑resolution detection of small pancreatic lesions (≤1 cm).
- Multiphasic CT or MRI – assesses tumor size, local invasion, and metastases (often to the liver or regional lymph nodes).
- Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – functional imaging that identifies gastrinomas expressing somatostatin receptors; superior for locating occult disease.
- Upper endoscopy (EGD) – visualizes ulcer burden and can obtain biopsies to exclude malignancy.
Pathology
If surgical resection is performed, the tumor is examined histologically. Gastrinomas are well‑differentiated NETs (WHO grade 1–2) and stain positive for gastrin, synaptophysin, and chromogranin A.
Treatment Options
Management focuses on two goals: control of acid hypersecretion and eradication (or control) of the gastrinoma.
Acid‑Suppressive Therapy
- Proton‑pump inhibitors (PPIs) – high‑dose regimens (e.g., omeprazole 60 mg daily or equivalent) are first‑line. Doses may be titrated to keep gastric pH > 4.
- H2‑receptor antagonists – less potent; occasionally added for breakthrough symptoms.
- Potassium‑competitive acid blockers (P‑CABs) – such as vonoprazan, may be considered where PPIs are insufficient, though data in ZES are limited.
Surgical Management
Curative surgery is possible when the tumor is localized.
- Enucleation – removal of small (<2 cm) isolated gastrinomas.
- Pancreaticoduodenectomy (Whipple) or distal pancreatectomy – for larger or multiple lesions.
- Liver metastasectomy – when hepatic spread is limited.
In MEN‑1 patients, surgery is more selective because multiple micro‑tumors are common; aggressive resection may not improve survival and can increase morbidity.
Medical (Non‑surgical) Therapies
- Somatostatin analogues (octreotide, lanreotide) – bind somatostatin receptors, decreasing gastrin secretion and controlling tumor growth.
- Targeted therapy (everolimus, sunitinib) – approved for advanced pancreatic NETs; can stabilize disease.
- Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to receptor‑positive tumors; emerging data show benefit in refractory ZES.
- Chemotherapy – reserved for high‑grade or poorly differentiated neuroendocrine carcinomas.
Lifestyle & Supportive Measures
- Limit alcohol and caffeine, which stimulate acid production.
- Avoid NSAIDs and aspirin unless directed by a physician.
- Small, frequent meals to reduce gastric load.
- Supplement calcium and vitamin D if osteoporosis risk is present.
Living with Zollinger‑Ellison Clinical Syndrome
Long‑term management requires a partnership between you, your gastroenterologist, and an endocrinologist or oncologist.
Daily Management Tips
- Medication adherence – take PPIs exactly as prescribed; never skip doses.
- Regular monitoring – serum gastrin, chromogranin A, and imaging every 6–12 months (or sooner if symptoms change).
- Symptom diary – note ulcer pain, stool frequency, and any new abdominal discomfort; share with your provider.
- Nutrition – a dietitian can help plan low‑fat, high‑protein meals that are easier to digest; consider medium‑chain triglyceride (MCT) oils if steatorrhea is severe.
- Bone health – weight‑bearing exercise and periodic bone density scans (DEXA) are recommended.
- Psychosocial support – chronic disease can be stressful; counseling or support groups (e.g., NET patient organizations) are valuable.
Prevention
Because most ZES cases are sporadic, primary prevention is limited. However, the following measures can reduce overall risk of neuroendocrine tumors and mitigate complications:
- Quit smoking; tobacco is a known risk factor for pancreatic NETs.
- Maintain a healthy weight and limit excessive alcohol intake.
- For individuals with known MEN‑1, undergo genetic counseling and routine surveillance (annual biochemical testing and imaging) to detect gastrinomas early.
- Promptly treat H. pylori infection and avoid chronic use of ulcer‑inducing medications unless medically necessary.
Complications
If untreated or inadequately controlled, ZES can lead to serious health problems:
- Bleeding ulcers – can cause melena, anemia, or life‑threatening hemorrhage.
- Gastrointestinal perforation – a surgical emergency.
- Obstruction – duodenal or gastric outlet blockage from scarring.
- Malabsorption & nutritional deficiencies – especially fat‑soluble vitamins (A, D, E, K) leading to night blindness, coagulopathy, or bone disease.
- Metastatic disease – ~60–70 % of sporadic gastrinomas have liver metastases at diagnosis; metastatic NETs can cause hormonal syndromes and organ dysfunction.
- Secondary cancers – MEN‑1 patients have increased risk of pituitary, parathyroid, and other pancreatic tumors.
When to Seek Emergency Care
- Sudden, severe abdominal pain that does not improve with usual medication.
- Vomiting blood (bright red or “coffee‑ground” material) or black, tarry stools.
- Signs of shock: rapid heartbeat, fainting, cold/clammy skin, or confusion.
- Uncontrolled diarrhea leading to dehydration (dry mouth, dizziness, little or no urine output).
- Severe difficulty breathing or choking sensation after vomiting.
These symptoms may signal a bleeding ulcer, perforation, or severe electrolyte imbalance—situations that require immediate medical attention.
References
- Mayo Clinic. Zollinger‑Ellison Syndrome. Updated 2023. https://www.mayoclinic.org/…
- National Institutes of Health (NIH) – Neuroendocrine Tumors Fact Sheet, 2022.
- Cleveland Clinic. MEN‑1 and Gastrinomas. 2024. https://my.clevelandclinic.org/…
- World Health Organization. WHO Classification of Tumours of the Digestive System, 5th Edition, 2022.
- American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Neuroendocrine Tumors. 2023.